ClinicalTrials.gg
CompletedNCT03649152ACTIONUpdated Jul 29, 2022

Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan

A Phase 2 interventional study of Propagermanium and Placebo in Focal Segmental Glomerulosclerosis, sponsored by Dimerix Bioscience Pty Ltd. Completed at 11 sites in Australia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-29.

Sponsored by Dimerix Bioscience Pty Ltd · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study will be evaluating the safety and efficacy of propagermanium for the treatment of participants with FSGS who are already taking irbesartan by:

  • monitoring symptoms that participants may experience while on the study,
  • measuring levels of protein in participant's urine and kidney function during the course of the study,
  • measuring the levels of propagermanium and irbesartan that enters into participant's urine and blood, and
  • comparing the propagermanium outcomes to participants' pre-study and placebo outcomes.

Eligible participants will randomly be assigned to one of two arms to receive both the propagermanium and placebo in different orders as follows, either:

Treatment Period 1 taking a propagermanium capsule twice a day for 16 weeks, followed by a six week washout period followed by Treatment Period 2 taking a placebo capsule twice a day for 16 weeks.

OR Treatment Period 1 taking a placebo capsule twice a day for 16 weeks, followed by a six week washout period followed by Treatment Period 2 taking a propagermanium capsule twice a day for 16 weeks.

02

Conditions studied

  • Focal Segmental Glomerulosclerosis
03

In context

Glomerulosclerosis, Focal Segmental

106 studies on the registry are indexed under Glomerulosclerosis, Focal Segmental; 34 are open to participants now.

This study's enrollment of 8 is below the median of 30 across 73 interventional studies indexed under Glomerulosclerosis, Focal Segmental.

Browse Glomerulosclerosis, Focal Segmental studies →

Lead sponsor

Dimerix Bioscience Pty Ltd is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 80 (inclusive) at screening;
  2. A diagnosis of primary FSGS confirmed by renal ;
  3. Must be receiving a stable dose of 300 mg daily dose of irbesartan (in any marketed formulation) for at least 3 months prior to screening, and have no plan to change treatment regime throughout the study;
  4. Patients can be on stable doses of angiotensin converting enzyme inhibitors, aldosterone inhibitors, direct renin inhibitor and/or sodium-glucose co-transporter- 2 inhibitors. However, the dose and regimen must be stable for 3 months prior to screening and must have no plan to change treatment regime throughout the study.
  5. If taking medications (except for rituximab or cyclophosphamide), must have a stable treatment regime for 3 months prior to screening and do not have plans to alter the regimen except to maintain therapeutic immunosuppression or in the event of adverse events. Patients who have received rituximab or cyclophosphamide must have ceased treatment for at least 6 months prior to screening;
  6. Mean of two protein/creatinine ratio values (screening and baseline) of ≥ 1326 mg/g (150 mg/mmol), and within ± 30% of the screening value at the baseline assessment;
  7. Estimated ≥ 25 mL/min/1.73 m\^2 using chronic kidney disease epidemiology collaboration (CKD-EPI) formula at screening;
  8. Serum potassium levels (screening and baseline) \< 5.5 mmol/L. If either value is 5.5 or above, the patient may receive dietary advice and be retested 1 week later;
  9. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

    • Not of , defined as surgically sterile (documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or (no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone [FSH] level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.);
    • Of childbearing potential and agrees to use a highly effective method of contraception consistently during the treatment period and for at least 60 days after the last dose of product;
  10. A male patient with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception during the treatment period and for at least 60 days after the last dose of investigational product and refrains from donating sperm during this period;
  11. Have given written prior to any study procedures being performed.

Exclusion criteria

Exclusion Criteria:

  1. Has FSGS secondary to another condition;
  2. A history of type 1 diabetes mellitus, diagnosis of type 2 diabetes mellitus prior to FSGS positive renal , or non-fasting blood glucose > 180 mg/dL (10 mmol/L) at screening;
  3. A prior kidney organ or stem cell transplant;
  4. A major adverse cardiac event within 6 months before screening;
  5. Lymphoma, leukaemia, or any within the past 5 years except for basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ that have been resected with no evidence of disease for 3 years;
  6. Jaundice, active hepatitis, or known hepatobiliary disease (except asymptomatic cholelithiasis);
  7. and/or aspartate aminotransferase more than two times the at screening;
  8. Participation in any clinical study with an experimental medication or device within 90 days or 5 half-lives (whichever is longer) of screening or have previously participated in a study involving propagermanium;
  9. Positive screening assessment for viral surface antigen or virus (HCV) antibody AND positive HCV RNA or (HIV), or a history of illicit drug injecting;
  10. Seated blood pressure of ≥ 160/100 mmHg at screening;
  11. ≥ 35 kg/m\^2 at screening;
  12. Past hospitalisation for a major depressive episode;
  13. Is breast feeding or pregnant;
  14. Unable to comply with the study procedures and assessments, including the ability swallow capsules;
  15. Any other disease, physical or psychological condition that the investigator or sponsor believes may contraindicate the use of the medicinal product or affect the interpretation of study results or render the patient at high risk from treatment complications;
  16. Are investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Propagermanium then Placebo

    Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary. Participants will receive 16 weeks propagermanium and 16 weeks placebo separated by a 6 week washout period.

    Drug: Propagermanium · Drug: Placebo

  • Experimental
    Placebo then Propagermanium

    Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary. Participants will receive 16 weeks placebo and 16 weeks propagermanium separated by a 6 week washout period.

    Drug: Propagermanium · Drug: Placebo

Interventions

  • Immediate release capsule

    Also known as: PPG, repagermanium, DMX-200

  • DrugPlacebo

    Placebo capsule

06

What researchers measure

Primary outcomes

  1. The Number of Adverse Events with the Adjunct use of Propagermanium Compared to Placebo in Participants with FSGS who are Receiving Irbesartan

    Assessed by monitoring of adverse events

    Time frame: Sixteen weeks

Secondary outcomes

  1. The Frequency of Proteinuria-Based Responses to Treatment Compared to Placebo

    Assessed by testing a 24-hour urine sample.

    Time frame: Sixteen weeks

07

Study locations

11 sites
  • Renal Research
    Gosford, New South Wales 2250, Australia
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • Westmead
    Westmead, New South Wales 2145, Australia
  • Sunshine Coast University Hospital
    Birtinya, Queensland 4575, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Austion Hospital
    Heidelberg, Victoria 3084, Australia
  • Sunshine Hospital
    Melbourne, Victoria 3021, Australia
  • Melbourne Renal Research Group
    Melbourne, Victoria, Australia
  • Epworth Hospital
    Richmond, Victoria 3121, Australia
08

References and documents

Publications

  • Hodson EM, Sinha A, Cooper TE. Interventions for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD003233. doi: 10.1002/14651858.CD003233.pub3. PubMed 35224732 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jun 2020, 19 months.

Of 17 phase 2 interventional studies under Glomerulosclerosis, Focal Segmental, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2018
First posted
Aug 28, 2018
StartActual
Nov 8, 2018
Primary completionActual
Jun 16, 2020
CompletionActual
Jul 13, 2020
Last update
Jul 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03649152
Lead sponsor
Dimerix Bioscience Pty Ltd
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Aug 28, 2018
Start date
Nov 8, 2018
Primary completion
Jun 16, 2020
Completion
Jul 13, 2020
Last update
Jul 29, 2022

Study contacts

Simon Roger, MD
principal investigator · Renal Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propagermanium

Start the discussion